State NH
Clinical Trials in New Hampshire
New Hampshire is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in New Hampshire and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 44 actively recruiting studies with New Hampshire sites out of 44 registered in total. The busiest research areas in New Hampshire are Epilepsy, Breast Cancer, Metastatic Breast Cancer. Leading sponsors running trials in the state include Dartmouth-Hitchcock Medical Center, Yale University, National Cancer Institute (NCI). By stage, New Hampshire trials break down as Phase 1 (4), Phase 2 (9), Phase 3 (15).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in New Hampshire
Frequently Asked Questions — Clinical Trials in New Hampshire
How many clinical trials are currently recruiting in New Hampshire?
ClinicalMetric currently tracks 44 actively recruiting clinical trials with at least one location in New Hampshire. The total number of registered studies—including active but not currently enrolling trials—is 44. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in New Hampshire?
New Hampshire hosts clinical trials across a broad range of medical conditions, including Epilepsy, Breast Cancer, Metastatic Breast Cancer, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout New Hampshire serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in New Hampshire?
To join a clinical trial in New Hampshire, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in New Hampshire maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in New Hampshire
NCT05796375 Phase 2
Recruiting
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder...
Condition
Non-muscle-invasive Bladder Cancer
Enrollment
240 pts
Location
United States
Sponsor
White River Junction Veterans
NCT05552222 Phase 3
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR)...
Condition
Multiple Myeloma
Enrollment
1,590 pts
Location
United States, Australia, Austria
Sponsor
Janssen Research & Development
NCT06975800 N/A
Recruiting
Effects of Social Feedback on Intracranial EEG
Condition
Social Influence
Enrollment
24 pts
Location
United States
Sponsor
Trustees of Dartmouth College
NCT06134375 Phase 1, Phase 2
Recruiting
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Condition
Triple Negative Breast Cancer
Enrollment
204 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT07085767 Phase 3
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/...
Condition
Breast Cancer
Enrollment
1,000 pts
Location
United States, Australia, Austria
Sponsor
Olema Pharmaceuticals, Inc.
NCT06039085 N/A
Recruiting
Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessme...
Condition
Prostate Cancer
Enrollment
200 pts
Location
United States
Sponsor
Ryan J. Halter
NCT06102486 N/A
Recruiting
MCI Speech in Noise
Condition
Mild Cognitive Impairment
Enrollment
70 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT06767514 Phase 3
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patie...
Condition
Non-Small Cell Lung Cancer
Enrollment
780 pts
Location
United States, Belgium, Canada
Sponsor
Summit Therapeutics
NCT07116967 Phase 3
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants Wit...
Condition
Plaque Psoriasis
Enrollment
3,040 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06898593 N/A
Recruiting
Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients
Condition
Anxiety Disorders
Enrollment
2,448 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT06030063 N/A
Recruiting
The Society for Obstetric Anesthesia and Perinatology Research Network General A...
Condition
Cesarean Delivery
Enrollment
5,000 pts
Location
United States, Canada
Sponsor
Yale University
NCT06747117 N/A
Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus ...
Condition
Lower Extremity Acute Limb Ischemia
Enrollment
300 pts
Location
United States, Australia, Brazil
Sponsor
Penumbra Inc.
NCT06080789 Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Part...
Condition
Acute Pancreatitis
Enrollment
36 pts
Location
United States, India
Sponsor
Panafina, Inc.
NCT02989948 N/A
Recruiting
Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA
Condition
Aortic Aneurysm, Thoracoabdominal
Enrollment
80 pts
Location
United States
Sponsor
Yale University
NCT07144150 N/A
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
Condition
Peripheral Vascular Disease
Enrollment
410 pts
Location
United States
Sponsor
Cook Research Incorporated
NCT07155187 Phase 2, Phase 3
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (...
Condition
Non-Small Cell Lung Cancer
Enrollment
490 pts
Location
United States, Australia, Austria
Sponsor
AbbVie
NCT05716516 Phase 2
Recruiting
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
Condition
Metastatic Breast Cancer
Enrollment
36 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT07362017 Phase 3
Recruiting
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate...
Condition
Moderate-to-severe Chronic Plaque Psoriasis
Enrollment
300 pts
Location
United States
Sponsor
Vanda Pharmaceuticals
NCT06258993 N/A
Recruiting
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise...
Condition
Breast Cancer
Enrollment
85 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT06172296 Phase 3
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Tre...
Condition
Ganglioneuroblastoma, Nodular
Enrollment
478 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
NCT05107466 N/A
Recruiting
Quantification of Visually Evoked Cortical Potentials in Individuals With Hearin...
Condition
Sensorineural Hearing Loss
Enrollment
100 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT04165070 Phase 1, Phase 2
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) ...
Condition
Carcinoma, Non-Small-Cell Lung
Enrollment
450 pts
Location
United States, Canada, Hungary
Sponsor
Merck Sharp & Dohme LLC
NCT05529264 N/A
Recruiting
Human Intracranial Electrophysiology
Condition
Epilepsy
Enrollment
175 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT06585410 Phase 3
Recruiting
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous S...
Condition
Cutaneous Squamous Cell Carcinoma (CSCC)
Enrollment
369 pts
Location
United States, Australia
Sponsor
Regeneron Pharmaceuticals
NCT06408298 EARLY_Phase 1
Recruiting
HCQ in Resectable Localized Prostate Cancer
Condition
Resectable Localized Prostate Cancer
Enrollment
20 pts
Location
United States
Sponsor
Lionel.D.Lewis, MD
Page 1 of 2 — 44 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology